Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Last trade$0.7474
Day change-$0.0027 (-0.35%)
Day range$0.705 – $0.824
Volume1,744,158
Market cap$32M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$32.27M
Price / earnings
—
Price / book
-2.44×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.5×
Profitability
Earnings per share
-$1.20
Return on assets
-939.79%
Return on equity
390.85%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
0.88×
Quick ratio
0.88×
Cash ratio
0.45×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$55.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ANVS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.19M
$2.37M
$1.29M
$955.15K
$1.14M
$1.11M
$1.27M
$1.74M
Research and development
$15.78M
$12.01M
$16.72M
$8.75M
$6.29M
$5.16M
$5.01M
$5M
Total operating expenses
$16.97M
$14.38M
$18.01M
$9.71M
$7.43M
$6.27M
$6.28M
$6.73M
Operating income
-$16.97M
-$14.38M
-$18.01M
-$9.71M
-$7.43M
-$6.27M
-$6.28M
-$6.73M
Interest expense
-$37.9K
-$1.59M
$0
$0
$0
$0
$0
$16.94K
Income before taxes
-$9.46M
-$14.82M
-$17.61M
-$9.83M
-$7.26M
-$6.22M
-$5.54M
-$5.86M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$9.46M
-$14.82M
-$17.61M
-$9.83M
-$7.26M
-$6.22M
-$5.54M
-$5.86M
Net income attributable to common shareholders
-$9.46M
-$14.82M
-$17.61M
-$9.83M
-$7.26M
-$6.22M
-$5.54M
-$5.86M
EBITDA
-$16.97M
-$14.38M
-$18.01M
-$9.71M
-$7.43M
-$6.27M
-$6.28M
-$6.73M
Basic earnings per share
-$0.22
-$0.40
-$0.63
-$0.38
-$0.37
-$0.32
-$0.32
-$0.42
Diluted earnings per share
-$0.22
-$0.40
-$0.63
-$0.38
-$0.37
-$0.32
-$0.32
-$0.42
Recent news
Company coverage with links to the original publishers.
Annovis Bio (NYSE: ANVS), a Phase 3 biotech company developing buntanetap for neurodegenerative diseases, received notice from the NYSE on October 29, 2026, that it no longer meets continued listing standards. The company's 30-day average market capitalization was approximately $48.4 million (below the $50 million threshold) and it reported a stockholders' deficit of $4.3 million as of June 30, 2026. Annovis has 45 days to submit a compliance plan and 9 months to regain compliance, during which its stock will trade with a '.BC' designation indicating below-criteria status. Failure to comply could result in NYSE delisting proceedings.
Annovis Bio (NYSE: ANVS) announced that its pivotal Phase 3 Alzheimer's disease trial has reached full enrollment with 850 patients, exceeding original projections. The company expects top-line data readout and regulatory submissions in 2027, with an open-label extension study beginning in October 2026. The company is also advancing its Parkinson's disease program with ongoing discussions with the FDA.
Annovis Bio will present two research presentations at the CTAD conference, highlighting biomarker data for buntanetap in treating Alzheimer's and Parkinson's diseases, focusing on potential disease-modifying therapeutic approaches.
The Alzheimer's disease market is expected to grow significantly between 2025-2034, driven by emerging therapies targeting disease mechanisms and improved diagnostic capabilities, with the US market representing approximately 50% of the total market size.
Annovis Bio, a late-stage clinical drug platform company, will present data from its latest Phase 3 Parkinson's disease and Phase 2/3 Alzheimer's disease studies at the AD/PD™ 2025 conference in Vienna.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.